Obesity, a global health concern characterized by excessive fat accumulation, necessitates the discovery of anti-obesity compounds. Rottlerin, known for its anti-cancer effects as a mitochondrial uncoupler, has been a subject of interest. However, its impact on reducing intracellular lipid accumulation remains a gap in our understanding. This study aimed to fill this gap by dissecting the mechanism of rottlerin in 3T3-L1 adipocytes. We treated differentiated 3T3-L1 cells with 0-20 mM of rottlerin for 48 hours to assess its capability to induce lipid accumulation. Notably, we observed no cytotoxicity associated with the treatment of rottlerin up to 20 mM, indicating its safety at these concentrations. Lipid accumulation, measured by oil Red O, was downregulated dose-independently by rottlerin. We also found that key lipogenic enzymes, including SCD1 and DGAT1, were decreased. The transcription factor of lipogenic genes, SREBP1, was reduced by approximately 80% with rottlerin. LRP6, a crucial link between de novo lipogenesis mechanism reactions and Wnt signaling, was also degraded by around 70%. Interestingly, the downstream regulation of LRP6, b-catenin, and TCFL2 was diminished by rottlerin. Our data indicate that rottlerin alleviates adipocyte lipid accumulation by suppressing the LRP6/β-catenin/SREBP1c pathway. These findings underscore the potential of rottlerin as a safe nutraceutical for combating obesity.

Obesity is the cause of many diseases, and its severity continues to increase. Promoting non-shivering thermogenesis is attracting attention as a new treatment strategy for obesity. This study summarized the studies that evaluated the effect of Panax ginseng on promoting non-shivering thermogenesis in animal models. A total of 7 studies were included according to the selection criteria, of which five were judged to have a high risk of bias. Indicators of UCP1 mRNA, UCP1 protein, and PGC- 1a were used in the meta-analysis, and the certainty of evidence progressed for each indicator, with UCP1 protein showing the highest certainty of evidence. Meta-analysis was conducted on 5 works of literature with standard indicators. As a result of meta-analysis, UCP1 protein level and PGC-1a mRNA level were significantly increased statistically. In addition, the protein levels of PRDM16 and TFAM increased in several studies (not a meta-analysis). These findings suggest that Panax ginseng could be a potential therapeutic agent for obesity. However, further research is needed to understand its mechanisms and possible side effects fully. Thus, it is concluded that Panax ginseng in animal models can promote non-shivering thermogenesis and improve mitochondria function in animal models, opening up new avenues for research and potential clinical applications.

Obesity, characterized by excessive fat accumulation, poses global health risks, including metabolic disorders like type 2 diabetes and cardiovascular diseases, with its prevalence steadily rising. This study proposes that rottlerin induces anti-obesity effects by enhancing non-shivering thermogenesis in beige adipocytes D16 via LRP6 inhibition. As a result, treatment of D16 cells with rottlerin up to 5 mM showed no cytotoxicity. Rottlerin significantly increased the expression of proteins involved in substrate oxidation, such as UCP1 and PGC1a, while decreasing the expression of C/EBPb associated with adipogenesis. Additionally, PRDM16, regulating brown adipocyte development, exhibited increased expression. The phosphorylation of LRP6, an indicator for Wnt signaling and nutrient-sensing pathway, is decreased by rottlerin. In conclusion, the study highlights the reduced phosphorylation of LRP6 as a pivotal mechanism by which rottlerin promotes the “beigeing” of D16 adipocytes, subsequently inducing non-shivering thermogenesis. This underscores rottlerin’s potential as a natural bioactive compound with anti-obesity effects.

Cardiovascular disease remains a leading global cause of mortality, demanding effective prevention and management. This systematic review explores the impact of lycopene, prevalent in various fruits, on cardiovascular health. Thirteen randomized and controlled trials were analyzed, involving 385 participants with cardiovascular risk factors. Notable findings included significant blood pressure reductions, particularly among hypertensive individuals, and favorable alterations in lipid profiles. Lycopene interventions also demonstrated potential in mitigating oxidative stress and inflammation markers. While these findings show promise, more rigorously designed studies are essential to determine optimal dosages and durations for precise cardiovascular benefits. In conclusion, lycopene shows potential in managing cardiovascular risk factors, and its role in blood pressure regulation, lipid profile improvement, and antioxidant and anti-inflammatory effects is encouraging. Nonetheless, further research is warranted to provide definitive guidance on integrating lycopene to enhance cardiovascular health.

이상의 결과를 종합하면, 혼합유산균 2종(Bifidobacterium animalis ssp. Lactis Bf141와 Lactobacillus rhamnosus Lb102)의 섭취는 고지방식이 유도 비만 마우스에서 체중, 체지방, 제지방, 골밀도 등 주요 체성분에 영향을 주지 않았다. 혼합유산균은 식욕 조절 효과를 위해 측정한 사료 섭취량에도 영향을 주지 않았으며, 간 조직 무게에도 영향을 미치지 않았다. 인슐린저항성과 포도당신생합성의 주요 지표인 공복혈당량 또한 혼합유산균 급여에 의해 변화 하지 않았다. 또한 혼합유산균은 심혈관질환의 지표로 사용되는 혈중 중성지방 및 총 콜레스테롤에 영향을 주지 않았으며, 체내 지방의 소화 및 흡수율에서도 영향을 미치지 않았다. 결론적으로, 고지방식이유도 비만 마우스를 이용하여 혼합유산균(Bf141 + Lb102)의 항비만 생리활성 을 검증한 결과, 유의미한 물리적, 대사적 표현형 개선은 검증되지 않았다. 따라서, 추후 개별 보다 다양한 혼합 조건 및 농도로 연구를 설계하여 혼합유산균의 항비만 효과를 검증할 필요성이 있다.